What are the possible causes of persistent low hemoglobin in a patient with sickle cell disease who is receiving hydroxyurea therapy?

Low Hemoglobin Despite Hydroxyurea in Sickle Cell Disease

The most critical first step is to verify hydroxyurea-induced myelosuppression by checking a complete blood count with differential, reticulocyte count, and assessing for dose-related toxicity, as this is a known adverse effect that requires immediate dose modification or discontinuation. 1

Immediate Assessment: Rule Out Hydroxyurea Toxicity

Myelosuppression is the primary concern when hemoglobin remains low or drops on hydroxyurea therapy. The FDA label explicitly warns that hydroxyurea causes severe myelosuppression, with anemia occurring less commonly than leukopenia but still representing a significant toxicity 1. You must obtain:

• CBC with differential and absolute reticulocyte count to assess for bone marrow suppression 2
• Hemolysis workup if there is acute jaundice, hematuria, or worsening anemia: LDH, haptoglobin, indirect bilirubin, urinalysis, and direct/indirect Coombs tests 1

If hemoglobin is <10 g/dL at the lowest dose required for clinical response, this meets criteria for hydroxyurea intolerance and the drug should be discontinued 3. If hemolytic anemia is confirmed and other causes excluded, discontinue hydroxyurea immediately 1.

Assess Medication Adherence and Fetal Hemoglobin Response

Poor adherence is a common and underrecognized cause of treatment failure. Studies demonstrate that deviation from personal best fetal hemoglobin (HbF) levels despite stable dosing strongly correlates with suboptimal adherence and increased acute care utilization 4.

• Check current HbF percentage and compare to the patient's historical peak (personal best) 4
• A decline of ≥20% from peak HbF despite stable dosing suggests poor adherence 4
• Baseline HbF, baseline hemoglobin, MTD dose, and compliance are the strongest predictors of HbF response 5

Even patients with low baseline HbF can achieve substantial increases at maximum tolerated dose, so low baseline alone should not discourage therapy 5.

Evaluate for Chronic Kidney Disease

Worsening anemia with concurrent drop in reticulocyte count in a patient on hydroxyurea should prompt evaluation for chronic kidney disease (CKD). 6

The American Society of Hematology 2019 guidelines specifically recommend:

• Combination therapy with hydroxyurea and erythropoiesis-stimulating agents (ESAs) for SCD patients with worsening anemia associated with CKD 6
• ESAs are appropriate when there is simultaneous drop in hemoglobin AND absolute reticulocyte count 6
• Do not exceed hemoglobin threshold of 10 g/dL (hematocrit 30%) to reduce risk of vaso-occlusive complications, stroke, and VTE 6

Consider Inadequate Dosing

Fixed low-dose hydroxyurea may be less effective than dose escalation to maximum tolerated dose. While some studies show clinical equipoise 7, current guidelines recommend escalation 2, 8.

• Standard starting dose is 15 mg/kg/day for HbSS or Sβ⁰-thalassemia 8
• For HbSC or Sβ⁺-thalassemia with severe disease, consider starting at 15 mg/kg due to increased cytopenia risk 8
• Dose reduction to 7.5 mg/kg/day is required for creatinine clearance <60 mL/min or ESRD 1

Monitor CBC and reticulocyte count every 1-3 months depending on dose stability 2. The HbF response can take weeks to months to fully manifest 9.

Alternative Explanations Beyond Hydroxyurea

Folic acid deficiency is no longer a concern given widespread supplementation of formula and grain products in Western countries 2. However, consider:

• Ongoing hemolysis from disease progression despite therapy 10
• Irreversible vascular damage that may not respond to HbF elevation 10
• Complications can still occur despite HbF levels >20%, as hydroxyurea does not eliminate all disease manifestations 10

Management Algorithm

1. Check CBC with differential, reticulocyte count, and hemolysis markers immediately 1
2. If hemoglobin <10 g/dL at lowest effective dose OR confirmed hemolytic anemia: discontinue hydroxyurea 3, 1
3. If reticulocyte count is low: evaluate for CKD and consider ESA therapy 6
4. Check HbF level and compare to personal best to assess adherence 4
5. If adherent with adequate dosing but poor response: consider dose escalation if not at MTD 8, 5
6. If at MTD with good adherence but persistent complications: consider alternative disease-modifying therapies (L-glutamine, voxelotor, crizanlizumab) or chronic transfusion therapy 2

Common pitfall: Assuming all low hemoglobin on hydroxyurea represents treatment failure, when it may actually represent drug toxicity requiring dose reduction or discontinuation rather than escalation.